Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche Has Hopes Of Accelerating Hematology Programs With Surrogate Endpoint

Executive Summary

Roche execs made surrogate endpoints the theme of the company’s recent late-stage pipeline review, highlighting in particular the possible use of minimal residual disease as a surrogate endpoint in the clinical trials for its hematologic agents.

You may also be interested in...



Breast Cancer Protection Plan In Place, Roche Turns Attention To Hematology

With new drugs at hand to protect its Herceptin breast cancer franchise, Roche announced positive data for its rituximab replacement candidate and other steps in its plan to protect top-seller Rituxan/MabThera.

Publisher’s Spotlight: Shortlist Revealed For The 2021 Citeline Awards

From a record more than 100 entries, the finalists have been selected for 12 awards, representing the best and brightest of biopharmaceutical research. 

Publisher’s Spotlight: Shortlist Revealed For The 2021 Citeline Awards

From a record more than 100 entries, the finalists have been selected for 12 awards, representing the best and brightest of biopharmaceutical research. 

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055675

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel